In Vitro Activities of Daptomycin against 2,789 Clinical Isolates from 11 North American Medical Centers
Open Access
- 1 June 2001
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (6), 1919-22
- https://doi.org/10.1128/aac.45.6.1919-1922.2001
Abstract
The in vitro activity of daptomycin is affected by the concentration of calcium cations in the test medium. Mueller-Hinton broth is currently adjusted to contain 10 to 12.5 mg of magnesium per liter and 20 to 25 mg of calcium per liter, but for testing of daptomycin, greater concentrations of calcium (50 mg/liter) are recommended to better resemble the normal concentration of ionized calcium in human serum. Two levels of calcium were used for broth microdilution tests of 2,789 recent clinical isolates of gram-positive bacterial pathogens. MICs of daptomycin were two- to fourfold lower when the broth contained additional calcium. For most species, however, the percentages of strains that were inhibited by 2.0 μg of daptomycin per ml were essentially identical with the two broth media. Enterococci were the important exception; i.e., 92% were inhibited when tested in calcium-supplemented broth but only 35% were inhibited by 2.0 μg/ml without the additional calcium. This type of information should be considered when selecting criteria for defining in vitro susceptibility to daptomycin.Keywords
This publication has 8 references indexed in Scilit:
- Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro testsDiagnostic Microbiology and Infectious Disease, 2000
- Daptomycin: a novel agent for Gram-positive infectionsExpert Opinion on Investigational Drugs, 1999
- Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococciAntimicrobial Agents and Chemotherapy, 1992
- Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremiaAntimicrobial Agents and Chemotherapy, 1992
- Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbitsAntimicrobial Agents and Chemotherapy, 1989
- Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendationsAntimicrobial Agents and Chemotherapy, 1989
- Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendationsAntimicrobial Agents and Chemotherapy, 1987
- In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibioticAntimicrobial Agents and Chemotherapy, 1986